Inspire V clinical data shows superior efficacy, adherence, and reduced surgical times; AHI cut from 34.4 to 8.3

Inspire Medical Systems, Inc.

Singapore study (44 patients): Inspire V IPOP 87.1% vs Inspire IV 79.4%, exceeding non-inferiority margin of 4.6%.
Median AHI reduced from 34.4 to 8.3 events/hour at 6 months for 37 Singapore patients.
US limited market release (101 patients): no serious adverse events; 100% therapy usage at 60 days; average adherence 6.8 hrs/night.
AHI for first 34 US patients dropped from 30 to 4.5 events/hour; average stimulation amplitude 1.7V.
20% reduction in surgical times; average implant time 34.5 minutes at one site; new internal respiratory sensing eliminates pressure lead.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.